Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al
- PMID: 32606045
- DOI: 10.1136/annrheumdis-2020-218328
Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al
Keywords: arthritis, rheumatoid; lupus erythematosus, systemic; spondylitis, ankylosing.
Conflict of interest statement
Competing interests: MG reports grants from National Institutes of Health, NIAMS, outside the submitted work. KLH reports she has received speaker’s fees from Abbvie and grant income from BMS, UCB and Pfizer, all unrelated to this manuscript. KLH is also supported by the NIHR Manchester Biomedical Research Centre. JY reports personal fees from Astra Zeneca, personal fees from Eli Lilly, grants from Pfizer, outside the submitted work. PMM reports personal fees from Abbvie, personal fees from Eli Lilly, personal fees from Novartis, personal fees from UCB, outside the submitted work. PCR reports personal fees from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, UCB Pharma and non-financial support from BMS and Roche outside the submitted work.
Comment on
-
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29. Ann Rheum Dis. 2020. PMID: 32471903 Free PMC article.
-
Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis.Ann Rheum Dis. 2021 Jun;80(6):e87. doi: 10.1136/annrheumdis-2020-218258. Epub 2020 Jun 30. Ann Rheum Dis. 2021. PMID: 32606044 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical